Source comparison
Do Peptides Help with Strength: Clinical Evidence Comparison
GHRP-2 Ghrelin receptor agonist; pulsatile GH release 1.8–3.2 kg 5–9% 2–3× daily (100mcg SC) Short half-life requires multiple daily injections; consistent results but logistically demanding for non-clinical use Hexarelin High-potency GHS; 10–12× baseline GH s
This comparison does not assign a generated winner or score.
- GHRP-2
- Ghrelin receptor agonist; pulsatile GH release
- 1.8–3.2 kg
- 5–9%
- 2–3× daily (100mcg SC)
- Short half-life requires multiple daily injections; consistent results but logistically demanding for non-clinical use
- Hexarelin
- High-potency GHS; 10–12× baseline GH spike
- 3.1–4.1 kg
- 8–12%
- 2× daily (2mcg/kg SC)
- Most potent acute GH response but receptor desensitisation after 4–6 weeks limits sustained use without cycling
- MK 677 (Ibutamoren)
- Oral ghrelin mimetic; 24-hour IGF-1 elevation
- 1.1–2.7 kg
- 6–11%
- 1× daily (25mg oral)
- Once-daily dosing with stable IGF-1 levels; best balance of efficacy, convenience, and sustained receptor sensitivity
- CJC-1295 + Ipamorelin
- GHRH analogue + selective GHS; synergistic GH release
- 2.0–3.5 kg
- 6–10%
- 1× daily (both 100mcg SC)
- Combines long-acting GHRH with GHS for amplified effect; requires reconstitution and injection expertise